#Switzerland #Geneva #Neurotherapeutics #MindMaze Therapeutics #Neuro.io

MindMaze Therapeutics Streamlines Operations and Secures Funding

MindMaze Therapeutics Holding SA, recognized for its pioneering advances in scalable precision neurotherapeutics, has recently achieved significant milestones aimed at refining its operational framework and securing essential funding. In an announcement made on August 10, 2026, the company detailed the completion of its organizational simplification initiative alongside an update regarding its CHF 8 million equity financing agreement with Neuro.io Group SA.

Completion of Organizational Simplification

The primary objective of MindMaze's organizational simplification was to streamline its operations by divesting from non-core neurology functions that were established through its acquisition of Relief Therapeutics. This strategic decision was made to reduce costs and concentrate efforts on strengthening its neurology focus, thereby enhancing efficiency and better aligning with its strategic priorities. The successful completion of this initiative involved a series of transactions, which included both immediate cash payments and potential contingent considerations in the future.

By focusing on its core operations, MindMaze aims to bolster its position in the global neurotherapeutics market, further utilizing its advanced software and proprietary sensors to provide innovative solutions for neurological disorders such as stroke and Parkinson's disease.

Update on Neuro.io Equity Financing

In conjunction with its restructuring efforts, MindMaze also announced a key update regarding its strategic equity financing partnership with Neuro.io. The company successfully completed the first phase of the CHF 8 million financing agreement, receiving gross cash proceeds of CHF 4 million. This transaction included the transfer of 4,970,000 treasury shares to Neuro.io and the conversion of CHF 2,850,900 mandatory convertible loan notes into 12,395,217 ordinary shares as stipulated by the agreement terms.

The financing has been structured into two tranches, with the second CHF 4 million tranche expected to be funded in two installments over September and November 2026, under a revised schedule that was mutually agreed upon by both parties. MindMaze assures that while there is no definitive timeline for the completion of this phase, the economic terms associated with the investment remain unchanged.

To continue supporting its operational liquidity, MindMaze is actively exploring additional financing channels and has committed to keeping its stakeholders informed of any substantial developments.

The Future of MindMaze Therapeutics

As a leader in innovative neurological treatment solutions, MindMaze Therapeutics combines advanced technology with extensive clinical validation to transform patient recovery paths. Its FDA-approved and CE-marked products address the critical shortage of specialized clinicians and offer scalable solutions for various neurological conditions. The company's vision is to create a seamless continuum of care from the hospital to outpatient and home-based rehabilitation.

With a robust research and development pipeline, MindMaze's strategies emphasize operational efficiency coupled with innovative therapeutic approaches to redefine neurorestorative medicine. Stakeholders can follow further updates directly through MindMaze Therapeutics' official website, which provides comprehensive insights into the company's mission and ongoing initiatives.

For an in-depth understanding of MindMaze’s commitment to enhancing neurological therapies, potential investors and interested parties are encouraged to explore ongoing projects and their real-world applications.

Conclusion

MindMaze Therapeutics is not only redefining its operational landscape but also positioning itself strategically within the neurotherapeutics realm. These recent changes and investments highlight the company's dedication to improving patient outcomes while maintaining a solid foundation for future growth and innovation in the neurological treatment landscape.